Physician profile
Corrinne Curry
NPI 1083158414
$4,435.23
in general payments reported to CMS, 2019-2025
37 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,216 · 2022: $781 · 2023: $687 · 2024: $939 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $342.04 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $304.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $302.68 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $263.16 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $240.48 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $235.20 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $194.98 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.95 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $159.47 | 2023-2024 | Rexulti |
| Medtronic, INC. | $157.50 | 2024 | Endurant Iis |
| Sanofi-Aventis U.S. LLC | $105.95 | 2021-2022 | |
| Amarin Pharma, INC. | $104.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.40 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $96.17 | 2022-2025 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $81.08 | 2023-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $64.62 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.11 | 2021-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $53.72 | 2022 | |
| Astellas Pharma US INC | $44.36 | 2021-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $42.58 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.66 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $35.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.27 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.76 | 2021 | |
| Silk Road Medical, INC. | $20.13 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Daiichi Sankyo INC. | $17.58 | 2023 | Injectafer |
| Dexcom, INC. | $17.18 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $17.06 | 2025 | Auvelity |
| Baxter Healthcare | $16.22 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Exact Sciences Corporation | $13.73 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $13.54 | 2025 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $13.50 | 2024 | Crysvita |
| Lundbeck LLC | $13.41 | 2021 | |
| Redhill Biopharma INC. | $12.67 | 2021 | |
| Eisai INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrinne Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.